|
|
|
|
|
Click Here to return To Results
|
|
|
|
Clinical data on 533 (95%) patients were available at 2 years. The relapse rate was significantly lower at 1 and 2 years with both doses of interferon B-1a than with placebo. Time to first relapse was prolonged by 3 and 5 months in the 22 ug and 44 ug groups respectively, and the proportion of relapse-free patients was significantly increased (p<0.05). Interferon B-1a delayed progression in disability, and decreased accumulated disability during the study. The accumulation of burden of disease and number of active lesions on MRI was lower in both treatment groups than in the placebo group. Subcutaneous interferon B-1a is an effective treatment for relapsing/remitting MS in terms of relapse rate, defined disability, and all MRI outcome measures in a dose-related manner, and it is well tolerated. Longer term benefits may become clearer with further followup and investigation. |
|
(click to filter results - removes previous filter)
disability,neurological
interferon
interferon beta 1-a
MRI
MRI,abnormal
MRI,serial
multiple sclerosis
multiple sclerosis,relapsing
multiple sclerosis,treatment of
treatment of neurologic disorder
|
Click Here to return To Results
|
|